A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects.

Trial Profile

A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2008

At a glance

  • Drugs PF 3864086 (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 15 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2008 Planned end date changed from 1 Nov 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 18 Nov 2008 Planned number of patients changed from 20 to 28 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top